Jennifer E Amengual
机构: Columbia University
每年引用次数
引用次数
引用: 2,078
H-指数: 22
I10-指数 : 36
出版物: 141
ETCTN P10500: PHASE 1/EXPANSION STUDY OF TAZEMETOSTAT PLUS BELINOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY LYMPHOMA.
JE Amengual , Y Shyr , D Durecki , JH Beumer
Hematological Oncology 41
2023
Utility of c-MYC Protein Expression in Prognosticating Aggressive B-Cell Non-Hodgkin Lymphomas
AA Allen , JE Amengual , B Alobeid , V Murty
LABORATORY INVESTIGATION 94 334A -334A
2014
SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA
R Karmali , A Donovan , N Wagner‐Johntson , M Messmer
Hematological Oncology 39
2021
Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL.
SS Tolu , MR Seshadri , Z Chen , E Orlando
Hematological Oncology 41
2023
ORAL AZACYTIDINE (AZA) AND ROMIDEPSIN (R) REVEALS PROMISING ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL TCell LYMPHOMA (PTCL)
OA O’Connor , J Lue , JE Amengual , A Sawas
2
2017
COMPLETE RESPONSES TO IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PREVIOUSLY TREATED WITH 5-AZACITIDINE: A POSSIBLE ROLE FOR EPIGENETIC PRIMING?
L Falchi , A Sawas , C Deng , JE Amengual
HAEMATOLOGICA 101 50 -50
2016
AN INTERNATIONAL MULTICENTER PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN AND BENDAMUSTINE IN PATIENTS WITH HEAVILY TREATED RELAPSED OR REFRACTORY HODGKIN LYMPHOMA AND ANAPLASTIC LARGE T-CELL LYMPHOMA DEMONSTRATES MARKED DURABLE RESPONSES
OA O'Connor , A Sawas , JM Connors , I Turenne
HAEMATOLOGICA 101 47 -47
2016
UBLITUXIMAB (TG-1101), A NOVEL ANTI-CD20 MONOCLONAL FOR RITUXIMAB RELAPSED/REFRACTORY B-CELL MALIGNANCIES
OA O'Connor , MT Schreeder , C Deng , JE Amengual
HAEMATOLOGICA 99 142 -143
2014
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13-17 June, 2023
C Pagès-Geli , S Bobillo , P Abrisqueta , J Castellví
Hematological oncology 41 739 -740
2023
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13-17 June, 2023
JE Amengual , P Reagan , H Li , H Saeed
Hematological oncology 41 102 -103
2023
Histone acetyltransferase (hat) regulators and uses thereof
Ottavio Arancio , Donald W. Landry , Shixian Deng , Jennifer Effie AMENGUAL
1
2022
Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States
Philip S Boonstra , Paolo Caimi , Mark S Kaminski , Hashim Abbas
Blood 130 377 -377
2017
Consolidation with Autologous Hematopoietic Cell Transplant in First Remission Improves Overall Survival in Younger Patients with Mantle Cell Lymphoma in the Rituximab Era
Kay Ristow , Oscar Calzada , David A Bond , Jennifer Kelly Anderson
Blood 130 341 -341
1
2017
A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)
Hyea Kim , Aishling M. Rada , Cremers Serge , Owen A. O'Connor
Blood 130 1515 -1515
9
2017
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Thomas M Habermann , Thomas E Witzig , Fangxin Hong , Nina Wagner-Johnston
Journal of Clinical Oncology 39 ( 12) 1329 -1338
3
2021
Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)
Owen A. O'Connor , Lorenzo Falchi , Jennifer Kimberly Lue , Francesca Montanari
Blood 132 1002 -1002
4
2018
Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience
Ahmed Sawas , John Kuruvilla , Jennifer Kimberly Lue , Changchun Deng
Blood 132 2907 -2907
1
2018
MAGE-A3 Inhibits p53 and Promotes Proliferation and Survival in Multiple Myeloma.
Hearn J. Cho , Anna Mei , Tricia Nardiello , Maurizio DiLiberto
Blood 114 ( 22) 1795 -1795
2009
The ATM Inhibitor KU60019 Synergizes the Antineoplastic Effect of Romidepsin in Mantle Cell Lymphoma (MCL)
Luigi Scotto , Xavier Jirau-Serrano , Kelly Zullo , Michael Mangone
Blood 126 ( 23) 3703 -3703
2015